Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative tissue-specific therapies for oncology and inflammatory diseases. With its headquarters in Los Angeles, California, the company is advancing a robust pipeline of drug candidates aimed at addressing unmet medical needs in both the United States and Australia. Immix is committed to leveraging cutting-edge research and strategic partnerships to bring transformative therapies to market, positioning itself as a noteworthy player in the biopharmaceutical landscape.